Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk

Luca Miele, Cristina Bosetti, Federica Turati, Gianlodovico Rapaccini, Antonio Gasbarrini, Carlo La Vecchia, Stefania Boccia, Antonio Grieco

Research output: Contribution to journalArticle

Abstract

Introduction. Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and antidiabetic treatments on HCC. Methods. Data derived from a hospital-based case-control study (Italy, 2005-2012) on 224 HCC patients and 389 controls. Odds ratios (ORs) were estimated using multiple logistic regression models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a diabetes diagnosis, corresponding to a multivariate OR of 2.25 (95% confidence interval, CI = 1.42-3.56). A stronger excess risk emerged for a longer time since diabetes diagnosis (OR = 2.96 for

Original languageEnglish
Article number570356
JournalGastroenterology Research and Practice
Volume2015
DOIs
Publication statusPublished - 2015

    Fingerprint

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this